| Availability, price and affordability of asthma medicines in five Indian states. | |
| | |
MedLine Citation:
|
PMID: 19383189 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
SETTING: States of Haryana, Karnataka, Maharashtra and Rajasthan, and Chennai (capital of Tamil Nadu State), India. OBJECTIVE: To assess the availability, price and affordability of beclomethasone and salbutamol inhalers in five Indian states using a standardised methodology. DESIGN: Data on the availability and price of two essential medicines for asthma, beclomethasone (50 microg/dose) and salbutamol (0.1 mg/dose) inhalers, were collated from five medicine price studies on essential medicines. RESULTS: Beclomethasone and salbutamol inhalers were available in 25% and 30% of public facilities in Rajasthan State only. The procurement price for beclomethasone and salbutamol was respectively 0.74 and 0.56 times the international reference price (IRP). The availability of beclomethasone inhalers was poor in the private sector (10-65%) in four states. The availability of salbutamol inhalers ranged from 20% to 95% as an innovator brand and 83% to 100% as the generic. The price of beclomethasone was 0.87-1.49 times the IRP, while salbutamol cost 0.82-1.12 times the IRP. Purchasing one inhaler each of salbutamol and beclomethasone cost between 1.6 and 2.3 days' wages for the lowest paid government worker. Eighty per cent of the population earn less than this wage. CONCLUSIONS: Essential inhalation medicines for asthma were not available in the public sector where low-income populations receive treatment. Steroid inhalers were not readily available in the private sector. Essential inhalation medicines for asthma are not affordable for the majority of the population. |
| | |
Authors:
|
A Kotwani |
Related Documents
:
|
2003939 - Reporting of preliminary data: time to take our sonographers "off the hook". 10241429 - The privacy implications of insurers' information practices. 19756169 - The moral organization of the professions: bioethics in the united states and france. 10552099 - Profile: comparative analysis of new zealand and us approaches for agricultural nonpoin... 22361109 - Values, attitudes and perceptions of managers as predictors of corporate environmental ... 8177769 - Career development. opportunity 2000. 11357759 - Risk management--why bother? 20112889 - Management of erectile dysfunction. 3052389 - Treatment of secretory otitis media with kampo medicine. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease Volume: 13 ISSN: 1027-3719 ISO Abbreviation: Int. J. Tuberc. Lung Dis. Publication Date: 2009 May |
Date Detail:
|
Created Date: 2009-04-22 Completed Date: 2009-07-09 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9706389 Medline TA: Int J Tuberc Lung Dis Country: France |
Other Details:
|
Languages: eng Pagination: 574-9 Citation Subset: IM |
Affiliation:
|
Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India. anitakotwani@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Asthmatic Agents
/
economics*,
supply & distribution* Asthma / drug therapy*, economics Drug Costs* Drugs, Essential / economics, supply & distribution Health Services Accessibility / economics* Humans India Population Surveillance Private Sector / economics Public Sector / economics Retrospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Asthmatic Agents; 0/Drugs, Essential |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB.
Next Document: Health-related quality of life among Koreans with chronic respiratory disease.